{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:20:24Z","timestamp":1781641224550,"version":"3.54.5"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The University of Milan"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Data on the role of hypothyroidism in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis are conflicting, although selective Thyroid Hormone Receptor (THR)-\u03b2 agonists have been identified as potential therapy in patients with non-alcoholic steatohepatitis (NASH). Therefore, we investigated the association between hypothyroidism and NAFLD histological features potentially associated with progressive liver disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Between 2014 and 2016, consecutive patients with histologically proven NAFLD and frozen serum available for thyroid function tests assessment were included. NAFLD was staged according to the NAFLD Activity Score (NAS), and fibrosis according to Kleiner. NASH was defined as NAS \u22654, significant fibrosis as F2-F4 and significant steatosis as S2-S3. Thyroid function tests (TFT; TSH, FT3, FT4, rT3), TPO-Ab and Tg-Ab were also assessed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Fifty-two patients were analyzed: median age 54 years, 58% females, LSM 7.8 kPa, 27% diabetics, 14% hypothyroid. At histology, NASH was present in 21 (40%), F2-F4 in 28 (54%) and S2-S3 in 30 (58%) patients. Rates of hypothyroidism were similar independently of the presence of NASH (p = 0.11), significant fibrosis (p = 0.21) or steatosis (p = 0.75). However, hypothyroid patients displayed a higher NAS (p = 0.02) and NASH (p = 0.06) prevalence. At multivariate analysis, TFT were not independently associated with histology.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Hypothyroidism was highly prevalent in NAFLD patients, and was associated with increased NAFLD activity, but not with fibrosis and steatosis severity. Thus, thyroid dysfunction might play a direct and\/or indirect in the pathogenesis of NAFLD and NASH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0249614","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T17:30:07Z","timestamp":1617730207000},"page":"e0249614","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-1153","authenticated-orcid":true,"given":"Roberta","family":"D'Ambrosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Giammona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Stucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-8441","authenticated-orcid":true,"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Persani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"pone.0249614.ref001","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"pone.0249614.ref002","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"GC Farrell","year":"2006","journal-title":"Hepatology"},{"key":"pone.0249614.ref003","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"MR Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"pone.0249614.ref004","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes\u2013 2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"pone.0249614.ref005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000454920","article-title":"Nonalcoholic fatty liver disease is not associated with thyroid hormone levels and hypothyroidism: a systematic review and meta-analysis","volume":"6","author":"V Jaruvongvanich","year":"2017","journal-title":"Eur Thyroid J"},{"key":"pone.0249614.ref006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fendo.2017.00335","article-title":"Relationship between hypothyroidism and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"8","author":"W He","year":"2017","journal-title":"Front Endocrinol"},{"key":"pone.0249614.ref007","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis","volume":"50","author":"Z Guo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"pone.0249614.ref008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/thy.2006.16.73","article-title":"Thyroid function in humans with morbid obesity","volume":"16","author":"MA Michalaki","year":"2006","journal-title":"Thyroid"},{"key":"pone.0249614.ref009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1381\/096089204323013514","article-title":"Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity","volume":"14","author":"Y Raftoupoulos","year":"2004","journal-title":"Obes Surg"},{"key":"pone.0249614.ref010","first-page":"1257","article-title":"Patterns of liver gene expression governed by TRbeta","volume":"16","author":"A Flores-Morales","year":"2002","journal-title":"Mol Endocrinol"},{"key":"pone.0249614.ref011","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.3748\/wjg.v19.i45.8238","article-title":"Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment","volume":"19","author":"YY Huang","year":"2013","journal-title":"World J Gastroenterol"},{"key":"pone.0249614.ref012","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1038\/sj.ijo.0801292","article-title":"Thyroid and lipid metabolism","volume":"24","author":"E Pucci","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"pone.0249614.ref013","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2014.07.001","article-title":"Throid hormone regulation of hepatic lipid and carbohydrate metabolism","volume":"25","author":"RA Sinha","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"pone.0249614.ref014","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40618-020-01208-6","article-title":"The interplay between thyroid and liver: implications for clinical practice","volume":"43","author":"E Piantanida","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"pone.0249614.ref015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1152\/ajpendo.00436.2004","article-title":"Thyroid hormone regulates tubulin expression in mammalian liver. Effects of deleting thyroid hormone receptor-alpha or -beta","volume":"289","author":"CG Vallejo","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"pone.0249614.ref016","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1172\/JCI60580","article-title":"Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy","volume":"122","author":"RA Sinha","year":"2012","journal-title":"J Clin Invest"},{"key":"pone.0249614.ref017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"PN Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"pone.0249614.ref018","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"SA Harrison","year":"2019","journal-title":"Lancet"},{"key":"pone.0249614.ref019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12902-015-0030-5","article-title":"EMIL-Study subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years","volume":"15","author":"U Ludwig","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"pone.0249614.ref020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1210\/jc.2005-0960","article-title":"Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism","volume":"91","author":"G Dimitriadis","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0249614.ref021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/cs1040007","article-title":"Response of glucose disposal to hyperinsulinemia in human hypothyroidism and hyperthyroidism","volume":"104","author":"C Rochon","year":"2003","journal-title":"Clin Sci"},{"key":"pone.0249614.ref022","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0025-6196(12)60694-6","article-title":"Hyperlipidemia in patients with primary and secondary hypothyroidism","volume":"68","author":"T O\u2019Brien","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"pone.0249614.ref023","first-page":"1","article-title":"Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population","volume":"154","author":"A Martinez Escud\u00e8","year":"2020","journal-title":"Med Clin"},{"key":"pone.0249614.ref024","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3350\/cmh.2015.21.4.372","article-title":"Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study","volume":"21","author":"Lee Kw","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"pone.0249614.ref025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"M Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"pone.0249614.ref026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"pone.0249614.ref027","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathological diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"NASH Clinical Research Network (CRN)","year":"2011","journal-title":"Hepatology"},{"key":"pone.0249614.ref028","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"pone.0249614.ref029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2265.2011.04016.x","article-title":"Association between thyroid function and nonalcoholic fatty liver disease I euthyroid elderly Chinese","volume":"75","author":"C Xu","year":"2011","journal-title":"Clin Endocrinol"},{"key":"pone.0249614.ref030","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.3748\/wjg.v20.i25.8102","article-title":"Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review","volume":"20","author":"A Eshraghian","year":"2014","journal-title":"World J Gastroenterol"},{"key":"pone.0249614.ref031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with non-alcoholic steatohepatitis and fibrosis","volume":"16","author":"D Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0249614.ref032","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10620-011-2006-2","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease","volume":"57","author":"MR Pagadala","year":"2012","journal-title":"Dig Dis Sci"},{"key":"pone.0249614.ref033","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1590\/S0004-28032011000300006","article-title":"Glyco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease","volume":"48","author":"DFC Mazo","year":"2011","journal-title":"Arq Gastroenterol"},{"key":"pone.0249614.ref034","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11739-011-0609-4","article-title":"Is nonalcoholic hepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?","volume":"8","author":"L Carulli","year":"2013","journal-title":"Intern Emerg Med"},{"key":"pone.0249614.ref035","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of non-alcoholic fatty liver disease: the Rotterdam Study","volume":"101","author":"A Bano","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0249614.ref036","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s10620-019-05687-3","article-title":"Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for non-alcoholic steatohepatitis","volume":"64","author":"P Manka","year":"2019","journal-title":"Dig Dis Sci"},{"key":"pone.0249614.ref037","first-page":"5753039","article-title":"Benefits of levothyroxine replacement therapy on non-alcoholic fatty liver disease in subclinical hypothyroidism patients","volume":"2017","author":"L Liu","year":"2017","journal-title":"Int J Endocrinol"},{"key":"pone.0249614.ref038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"R Taub","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T17:30:35Z","timestamp":1617730235000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249614"}},"subtitle":[],"editor":[{"given":"Pavel","family":"Strnad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0249614","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}